Goodbody Health (Goodbody Health) Change In Working Capital : $0.33 Mil (TTM As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Goodbody Health Change In Working Capital?

Goodbody Health's change in working capital for the quarter that ended in Sep. 2022 was $0.11 Mil.

Goodbody Health's change in working capital for the fiscal year that ended in Dec. 2021 was $1.88 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Goodbody Health Change In Working Capital Historical Data

The historical data trend for Goodbody Health's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goodbody Health Change In Working Capital Chart

Goodbody Health Annual Data

Trend

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Dec21

Change In Working Capital

Get a 7-Day Free Trial

0.01

-0.01

-0.95

0.01

1.88

Goodbody Health Quarterly Data
	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Working Capital	Get a 7-Day Free Trial															0.07	2.22	-0.47	-1.53	0.11

Goodbody Health Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Goodbody Health Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Goodbody Health's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Goodbody Health (Goodbody Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Goodbody Health Ltd (OTCPK:GDBYF) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Stubbs Lane, Beckington Frome, The Blue Building, Somerset, GBR, BA11 6TE

Website

https://www.goodbodyhealth.com

Goodbody Health Ltd is a wellness company operating in both COVID testing in the United Kingdom and as a vertically integrated cannabinoid CBD company that operates in the United Kingdom and the European Union. It has interests in COVID testing clinics, CBD extraction, wholesale bulk isolate, and distillate sales, retail CBD and white label sales, cannabinoid laboratory testing, and medicinal cannabis research programs.